COMPOSITION FOR USE IN THE PROMOTION OF INTESTINAL ANGIOGENESIS AND OF NUTRIENT ABSORPTION AND OF ENTERAL FEEDING TOLERANCE AND/OR IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL INFLAMMATION AND/OR IN THE RECOVERY AFTER INTESTINAL INJURY AND SURGERY

• US 20140286908A1
• Filed: 10/15/2012
• Published: 09/25/2014
• Est. Priority Date: 10/18/2011
• Status: Abandoned Application

• Current Assignee: Societe des Produits Nestle SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Sprenger, Norbert, Garcia-Rodenas, Clara
• Application Number:
  US14/352,231
• Publication Number:
  US 20140286908A1
• Time in Patent Office: Days
• US Class Current: 424/93.4
• CPC Class Codes: A23L 33/115 Fatty acids or derivatives thereof; Fats or oils
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/21 Addition of substantially indigestible substances, e.g. dietary fibres
• CPC Class Codes: A23L 33/30 Dietetic or nutritional methods, e.g. for losing weight A23L33/10 takes precedence
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61K 31/7016 Disaccharides, e.g. lactose, lactulose lactobionic acid A61K31/7032
• CPC Class Codes: A61K 31/702 Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation, such as necrotizing enterocolis, and/or in the recovery after intestinal injury and/or surgery. This composition is particularly adapted for use in infants, notably preterm infants.

Claims

1. A method for the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and/or surgery comprising administering to an individual in need of same a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides, the mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide.

2. A method according to claim 1, wherein the neutral oligosaccharide is selected from the group consisting of fructooligosaccharides (FOS) and galactooligosaccharides (GOS), preferably GOS.

3. A method according to claim 1, wherein the oligosaccharide mixture contains at least one N-acetylated oligosaccharide selected from the group comprising consisting of GalNAcα

1,3Galβ

1,4Glc (=3′

GalNAc-lac=N-acetyl-galactosaminyl-lactose), Galβ

1,6GalNAcα

1,3Galβ

1,4Glc (=6′

Gal-3GalNAc-lac=galactosyl-N-acetyl-galactosaminyl-lactose), Galβ

1,4GlcNAcβ

1,3Galβ

1,4Glc (lacto-N-neotetraose or LNnT) and Galβ

1,3GlcNAcβ

1,3Galβ

1,4Glc (lacto-N-tetraose or LNT), at least one sialylated oligosaccharide selected from the group consisting of NeuAcα

2,3Galβ

1,4Glc (=3′

-sialyllactose) and NeuAcα

2,6Galβ

1,4Glc (=6′

-sialyllactose), and at least one neutral oligosaccharide selected form the group consisting of Galβ

1,6Gal (=β

1,6-digalactoside);

Galβ

1,6Galβ

1,4Glc (=6′

Gal-lac);

Galβ

1,6Galβ

1,6Glc;

Galβ

1,3Galβ

1,3Glc;

Galβ

1,3Galβ

1,4Glc (=3′

Gal-lac);

Galβ

1,6Galβ

1,6Galβ

1,4Glc (=6′

,6-diGal-lac);

Galβ

1,6Galβ

1,3Galβ

1,4Glc (=6′

,3-diGal-lac);

Galβ

1,3Galβ

1,6Galβ

1,4Glc (=3′

,6-diGal-lac);

Galβ

1,3Galβ

1,3Galβ

1,4Glc (=3′

,3-diGal-lac);

Galβ

1,4Galβ

1,4Glc (=4′

Gal-lac) and Galβ

1,4Galβ

1,4Galβ

1,4Glc (=4′

,4-diGal-lac); and

Fucα

1,2Galβ

1,4Glc (=2′

fucosyllactose or FL).

4. A method according to claim 1, wherein the oligosaccharide mixture comprises:

0.25-20 wt %, preferably 0.3-10 wt % of at least one N-acetylated oligosaccharide;

0.5-30 wt %, preferably 0.75-15 wt % with respect to the total weight of the oligosaccharide mixture, of at least one sialylated oligosaccharide, and

50-99.3 wt % with respect to the total weight of the oligosaccharide mixture, of at least one neutral oligosaccharide.

5. A method according to claim 1, wherein the oligosaccharide mixture is present in an amount of 0.5-70% with respect to the total weight of the composition.

6. A method according to claim 1, wherein the LC-PUFA is selected from the group consisting of arachidonic acid (ARA) and docosahexanoic acid (DHA).

7. A method according to claim 1, wherein the probiotic is a probiotic bacterial strain.

8. A method according to claim 1, wherein the N-acetylated oligosaccharide is selected from the group consisting of lacto-N-neotetraose (or LNnT) and lacto-N-tetraose (or LNT).

9. A method according to claim 1, wherein the sialylated oligosaccharide is selected from the group consisting of 3′

-sialyllactose and 6′

-sialyllactose.

10. A method according to claim 1, wherein the neutral oligosaccharide is 2′

-fucosyllactose (or FL).

11. A method according to claim 1, wherein the composition is in a form selected from the group consisting of a preterm infant formula, a human milk fortifier, a starter infant formula, a follow-on formula, a baby food formula, an infant cereal formula, a growing-up milk, a medical food product for clinical nutrition and a supplement.

12. A method according to claim 1, wherein the individual is an infant or child.

13. A method for the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and/or surgery comprising administering to an individual in need of same a composition comprising at least one long chain polyunsaturated fatty acid (LC-PUFA), at least one probiotic and a mixture of oligosaccharides, the mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, as a synthetic nutritional agent.